💰 They received a £1 million grant to enhance efficiency and scalability in treatment production.
🌐 Collaborators include Resolution Therapeutics and CGT Catapult, among others.
👨🔬 This project aims to address manufacturing challenges, significantly increasing patient access to innovative therapies.
📅 It will last 20 months, focusing on advanced robotics and AI.
Introduction:
The article discusses an innovative collaborative project undertaken by Cellular Origins, Resolution Therapeutics, and the Cell and Gene Therapy Catapult (CGT Catapult) aimed at revolutionizing the process of cell therapy manufacturing. Equipped with a substantial grant from Innovate UK, the consortium is focused on the development of a fully automated and scalable manufacturing platform for cell and gene therapies (CGTs).
- The consortium’s project is funded by a £1 million Smart Grant from Innovate UK, launched on July 1, 2025, with a duration of 20 months.
- Participating organizations will leverage their unique expertise in automation, robotics, and manufacturing processes to enhance CGT production capabilities.
- Current manual manufacturing methods cannot scale efficiently, limiting production to just a few thousand doses annually, thus impacting patient access.
- The initiative aims to integrate Cellular Origins’ Constellation robotic platform within CGT Catapult’s Digital and Automation Testbeds, facilitating advanced testing environments.
- Resolution Therapeutics will contribute clinical and commercial expertise to the consortium, specifically targeting the development of their Regenerative Macrophage Therapy for serious liver diseases.
Conclusion:
This collaboration signifies a pivotal advancement in addressing the manufacturing challenges within the CGT sector. By integrating robotics and digital technologies, the consortium aims to enhance the scalability and cost-efficiency of CGT production, thereby improving patient access to life-saving therapies. The project also underscores the UK’s commitment to remain a leader in cell and gene therapy innovation.
